Article
Rheumatology
Christina Charles-Schoeman, Ernest Choy, Iain B. McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K. Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R. Curtis
Summary: This study provides an integrated analysis of major adverse cardiovascular events (MACEs) and venous thromboembolism (VTE) events in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients treated with upadacitinib. The results show that the rates of MACEs and VTE events with upadacitinib are similar to those reported for conventional synthetic and biologic disease-modifying drugs, and comparable to adalimumab and methotrexate.
Article
Biochemistry & Molecular Biology
Chia-Jung Tsai, Yu-Chih Lin, Chung-Yu Chen, Chih-Hsing Hung, Yi-Ching Lin
Summary: This retrospective study analyzed the impact of biologics and non-biologics treatment on the development of hematologic malignancies in patients with AS, psoriasis, and PsA. The results showed that biologics significantly increased the risk of hematologic malignancies, specifically non-Hodgkin's lymphoma. Different treatment patterns, types of biologics, cumulative defined daily doses, comorbidities, and comedications did not have a significant effect on hematologic malignancy development.
Article
Rheumatology
Anton Jonatan Landgren, Mats Dehlin, Lennart Jacobsson, Ulrika Bergsten, Eva Klingberg
Summary: The study aimed to compare traditional cardiovascular risk factors among patients with different rheumatic diseases, and found that hypertension was the most common comorbidity, with patients with gout having the highest prevalence of traditional CVRFs. Significant differences in occurrence of CVRFs by sex were also observed among patients with PsA, RA and AS.
Article
Medicine, General & Internal
Vandana Bhushan, Susan Lester, Liz Briggs, Raif Hijjawi, E. Michael Shanahan, Eliza Pontifex, Jem Ninan, Catherine Hill, Fin Cai, Jennifer Walker, Fiona Goldblatt, Mihir D. Wechalekar
Summary: Similar retention rates of the second and third compared to the first b/tsDMARD in RA, PsA, and AS support a differential b/tsDMARDs use strategy based on patient presentation. The risk of b/tsDMARD failure was halved in PsA patients, and covariates were not associated with the risk of bDMARD failure. The most common reason for switching was treatment failure.
FRONTIERS IN MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Nuria Carballo, Enric Garcia-Alzorriz, Olivia Ferrandez, Maria Eugenia Navarrete-Rouco, Xavier Duran-Jorda, Carolina Perez-Garcia, Jordi Monfort, Francesc Cots, Santiago Grau
Summary: This study evaluated the impact of treatment persistence on healthcare resource utilization costs in patients with immune-mediated rheumatic diseases. The findings suggest that persistent treatment with subcutaneous TNF-alpha inhibitors may lead to cost savings in healthcare resource utilization for these patients, highlighting the importance of prescribing therapies with optimal long-term persistence.
FRONTIERS IN PHARMACOLOGY
(2021)
Editorial Material
Rheumatology
Juergen Braun, Dietmar Krause, Uta Kiltz
Summary: This editorial discusses the impact evaluation of a nurse-led program for patient self-assessment and self-management in axial spondyloarthritis, presented in a prospective, multicenter, randomized, controlled trial (COMEDSPA) conducted by Anna Molto et al.
Article
Rheumatology
Gerd R. Burmester, Stanley B. Cohen, Kevin L. Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman-Yassky
Summary: This study evaluated the long-term safety of upadacitinib in patients with RA, PsA, AS, and AD. The analysis of safety data from clinical trials showed that upadacitinib was generally well tolerated in these diseases, with some differences in safety profiles.
Article
Medicine, Research & Experimental
Johan Dalen, Anushri Chitkara, Axel Svedbom, Tor Olofsson, Amy Puenpatom, Christopher M. Black, Zaina P. Qureshi
Summary: This study investigated the direct and indirect costs associated with non-persistence with subcutaneous TNF-alpha inhibitors in inflammatory arthritis patients in Sweden. The results showed that patients who remained persistent with treatment incurred significantly lower healthcare costs compared to patients who discontinued treatment, highlighting the economic impact of treatment persistence.
ADVANCES IN THERAPY
(2022)
Article
Rheumatology
Cindy L. J. Weinstein, Alan G. Meehan, Jianxin Lin, Steven D. Briscoe, Marinella Govoni
Summary: This study analyzed the long-term persistence of golimumab treatment in patients with rheumatic diseases over a period of five years. The findings showed that golimumab had consistently high retention rates when used as first-line therapy and lower rates when used as second-line therapy, with patients on second-line therapy having a longer disease duration.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Xabier Michelena, Clementina Lopez-Medina, Alba Erra, Xavier Juanola, Pilar Font-Ugalde, Eduardo Collantes, Helena Marzo-Ortega
Summary: This study compared the clinical and radiographical characteristics of axial psoriatic arthritis (PsA) with ankylosing spondylitis (AS) with psoriasis. It found that axial PsA is predominantly HLA-B27 negative and has different manifestations compared to AS with psoriasis. There is great heterogeneity in the definition of axial PsA from a clinical and imaging perspective.
Article
Biochemistry & Molecular Biology
Krzysztof Bonek, Ewa Kuca Warnawin, Anna Kornatka, Magdalena Plebanczyk, Tomasz Burakowski, Wlodzimierz Maslinski, Malgorzata Wislowska, Piotr Gluszko, Marzena Ciechomska
Summary: This study investigates the associations between miR signatures and cytokines, serum lipids, and disease activity in patients with PsA, AS, and RA. The results show the superiority of miR expressions in distinguishing between RA, PsA, and AS, and a unique regulatory pathway in PsA.
Article
Rheumatology
Theresa Hunter, Chi Nguyen, Julie Birt, Joseph Smith, Mingyang Shan, Hiangkiat Tan, Jeffrey Lisse, Keith Isenberg
Summary: This study compared pain medication use in AS, PsA, and RA patients over 2 years compared to matched controls, while also assessing changes in pain medication use before and after initiation of biologics. The results indicated a significant decrease in the use of NSAIDs, glucocorticoids, and opioids among these patients in the first year of treatment.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Luis Fernando Perez-Garcia, Esther Roder, Robbert J. Goekoop, Johanna M. W. Hazes, Marc R. Kok, Hieronymus T. W. Smeele, Ilja Tchetverikov, Annette H. M. Van der Helm-van Mil, Jos H. van der Kaap, Petra Kok, Bouwe P. Krijthe, Radboud J. E. M. Dolhain
Summary: This study is the first to demonstrate that inflammatory arthritis can impact male fertility. Men diagnosed with IA before and during the peak reproductive years have lower fertility rates, higher rates of childlessness, and more fertility problems.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Medicine, General & Internal
Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So -Young Bang, Hye-Soon Lee
Summary: This study analyzed the effects of biologic agents on pregnancy outcomes using a nationwide population-based database. The results suggest that biologic agent use may be associated with several adverse pregnancy outcomes, especially in patients who use biologics during pregnancy.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Review
Rheumatology
Deepak R. Jadon, Nadia Corp, Danielle A. van der Windt, Laura C. Coates, Enrique R. Soriano, Arthur Kavanaugh, Tim Raine, Florian Rieder, Stefan Siebert, Michel Zummer, Sergio Schwartzman, James T. Rosenbaum, Brigitte Michelsen, Ramasharan Laxminarayan, Dongze Wu, Latika Gupta, Beverly Ng, Hannah Jethwa, Nick De Windt, Tania Gudu, Joseph Hutton, Denis O'Sullivan, Michele M. Luchetti, Matthew Stoll, Jasvinder A. Singh, Rosario Peluso, Judith Rademacher, M. Elaine Husni
Summary: This study summarizes the efficacy and safety of advanced therapies for psoriatic arthritis in patients with related conditions, including Crohn's disease, ulcerative colitis, and noninfectious uveitis. The tumor necrosis factor inhibitor (TNFi) class appears to be effective and safe, while interleukin 12/23 inhibitors (IL-12/23i) show efficacy in Crohn's disease and ulcerative colitis. However, caution should be exercised when using interleukin 17 inhibitors (IL-17i) in patients with psoriatic arthritis at high risk of inflammatory bowel disease.
JOURNAL OF RHEUMATOLOGY
(2023)
Review
Rheumatology
Aurelie Najm, Carl S. Goodyear, Iain B. McInnes, Stefan Siebert
Summary: This review discusses the tissue, cellular, and molecular mechanisms underlying the clinical heterogeneity of PsA. It highlights the importance of tissue-based therapy in PsA treatment and its potential implications for improving clinical outcomes and trial design.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Rheumatology
Fraser R. Morton, Bhautesh Jani, Frances S. Mair, Philip McLoone, Jordan Canning, Sara Macdonald, Ross McQueenie, Stefan Siebert, Barbara Nicholl
Summary: This longitudinal observational study investigates the association between multimorbidity and hospitalizations in people with established and early rheumatoid arthritis (RA). Participants with RA and multiple long-term conditions (LTCs) had higher hospitalization rates and longer durations compared to those with RA alone. Additionally, the hospitalization rate and duration were higher in RA participants with LTCs than in non-RA controls.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Rheumatology
Stefan Siebert, Frank Behrens, Ennio Lubrano, Nicolas Martin, Mohamed Sharaf, Christine Contre, Elke Theander, Ruben Queiro, Miriam Zimmermann, Laure Gossec
Summary: This study aims to collect data on the long-term clinical practice of using guselkumab or interleukin-17 inhibitors for the treatment of PsA to understand drug persistence, effectiveness, and long-term safety. Data will be collected through electronic patient-reported outcomes and physician-completed assessments, along with safety data. The study will last for 36 months with an additional 24-week observation period.
RHEUMATOLOGY AND THERAPY
(2023)
Article
Rheumatology
Arno W. R. Van Kuijk, Mike T. Nurmohamed, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, T. Korotaeva, Frederic Lavie, Mohamed Sharaf, Wim Noel, Elke Theander, Josef S. Smolen, Laure Gossec, Irene E. van der Horst-bruinsma
Summary: The study found that female PsA patients had more severe disease characteristics before starting bDMARD treatment compared to males, with less improvement and lower treatment persistence. Further understanding of these differences may help improve therapeutic management in female PsA patients.
Article
Rheumatology
Hanna Johnsson, John Cole, Iain B. McInnes, Gerard Graham, Stefan Siebert
Summary: This study compares transcriptional changes in psoriasis and PsA skin for the first time, finding that immunoglobulin genes are upregulated in PsA skin lesions, which may have implications for its spread to other tissues.
Review
Critical Care Medicine
Linda Lapp, Marc Roper, Kimberley Kavanagh, Matt-Mouley Bouamrane, Stefan Schraag
Summary: This scoping review examines the current state-of-the-art dynamic prediction models for patient outcomes in the ICU. The review found that there is significant potential in developing dynamic prediction models to aid decision-making in real-time. However, most of the models focus on predicting mortality, and there is a need for further models to predict other serious complications.
JOURNAL OF INTENSIVE CARE MEDICINE
(2023)
Review
Veterinary Sciences
Verity Horigan, Robin Simons, Kim Kavanagh, Louise Kelly
Summary: Qualitative risk assessment (QRA) is a useful tool in animal health for estimating and managing disease risk. Standardizing the approach and addressing key elements such as risk description, probability combining, trade volume and time period, and uncertainty are crucial for improving the robustness of QRA results. Mathematical reasoning and objective methodologies have been developed to enhance the objectivity and accuracy of QRA.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Article
Medicine, General & Internal
Baraka Moshi, Nateiya Yongolo, Sanjura Mandela Biswaro, Hans Maro, Sakanda Linus, Stefan Siebert, William Nkenguye, Emma McIntosh, Febronia Shirima, Rosalia E. Njau, Alice A. Andongolile, Manasseh Joel Mwanswila, Jo E. B. Halliday, Stefanie Krauth, Kajiru Kilonzo, Richard William Walker, Gloria August Temu, Blandina T. Mmbaga
Summary: This study aimed to determine the number of stroke admissions and associated comorbidities at a referral hospital in Northern Tanzania. Results showed that 12.2% of the admissions between 2017 and 2019 were stroke patients, with a high proportion of hypertension and diabetes mellitus among them. The in-hospital mortality related to stroke was also high, highlighting the need for interventions to reduce non-communicable diseases and their complications.
Article
Rheumatology
Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert
Summary: In the COSMOS trial, guselkumab demonstrated efficacy in treating TNFi-IR PsA patients by reducing levels of effector cytokines associated with the IL-23/IL-17 pathway.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana V. Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Summary: This study evaluated the effects of ustekinumab or TNFi on patient-reported outcomes (PRO) and their association with effectiveness endpoints in PsA patients over a 3-year period. The results showed that both treatments led to improvements in PROs, with TNFi showing a greater improvement in work productivity.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Laure Gossec, Elke Theander, Soumya D. D. Chakravarty, Paul Bergmans, Frederic Lavie, Wim Noel, Mohamed Sharaf, Stefan Siebert, Josef S. S. Smolen
Summary: This post-hoc analysis evaluated the safety, effectiveness, and treatment persistence of ustekinumab in patients with PsA aged < 60 and >= 60 years. The results showed fewer adverse events in younger patients, and similar treatment response and persistence in both age groups.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Sizheng Steven Zhao, Stephanie R. Harrison, Antoni Chan, Nick Clarke, Charlotte Davis, Joe Eddison, William J. Gregory, Gareth T. Jones, Helena Marzo-Ortega, Daniel J. Murphy, Virinderjit Sandhu, Raj Sengupta, Stefan Siebert, Ben Thompson, Dale Webb, Max Yates, Karl Gaffney
Summary: Pharmacological management has improved significantly since the 2015 guideline on axial spondyloarthritis (axSpA) was released, incorporating new classes of biologic and targeted synthetic DMARDs, as well as treatment strategies like drug tapering. This evidence-based update aims to guide healthcare professionals in the UK on the pharmacological management of axSpA using b/tsDMARDs. The guidelines are intended for rheumatologists, nurses, allied health professionals, trainees, pharmacists, axSpA patients, and other stakeholders.
RHEUMATOLOGY ADVANCES IN PRACTICE
(2023)
Article
Rheumatology
Ciara D. O'Brien, George Kitas, Fiona D. Rayner, John F. Isaacs, Kenneth G. Baker, Arthur D. Pratt, Christopher Buckley, Karim Raza, Andrew Filer, Stefan Siebert, Iain McInnes, Andrew McGucken, Sally A. M. Fenton, BIOFLARE Consortium
Summary: This study aimed to determine the minimum number of monitoring days required to reliably estimate sedentary time, light-intensity physical activity, and moderate-intensity physical activity in people with Rheumatoid Arthritis (RA) across different levels of disease activity. The results showed that at least 4 monitoring days were required to reliably estimate sedentary time and light-intensity physical activity, while at least 5 monitoring days were required to reliably estimate behaviors across the movement continuum. This information is important for accurately assessing physical activity levels and sedentary behavior in RA patients and can help inform interventions for promoting physical activity and reducing sedentary time.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Pharmacology & Pharmacy
Ricardo Mesquita Camelo, Mariana Michel Barbosa, Luila Clicia Moura Henriques, Antony Paul Martin, Brian Godman, Augusto Afonso Guerra Junior, Francisco de Assis Acurcio, Juliana Alvares-Teodoro
Summary: The costs of hemophilia A treatment are increasing, and it is important to avoid the waste of clotting products. This study aimed to estimate the first-year waste of emicizumab prophylaxis for hemophilia A patients with inhibitors who failed immune tolerance induction (ITI) in Brazil. The results showed that waste was more pronounced for patients with lower body weight and shorter administration intervals, with the lowest waste observed in the regimen of every 4 weeks.
SAUDI PHARMACEUTICAL JOURNAL
(2023)
